
==== Front
Schizophrenia (Heidelb)
Schizophrenia (Heidelb)
Schizophrenia
2754-6993
Nature Publishing Group UK London

491
10.1038/s41537-024-00491-z
Article
Reduction of intracortical inhibition (ICI) correlates with cognitive performance and psychopathology symptoms in schizophrenia
Zhu Minghuan 1
Xu Yifan 2
Zhang Qi 1
Cheng Xiaoyan 1
Zhang Lei 1
Tao Fengzhi 1
Shi Jiali 1
Zhu Xingjia 1
Wang Zhihui 1
Zhao Xudong zhaoxd62@gmail.com

1
http://orcid.org/0000-0002-5808-1785
Liu Weiqing lwqkm2012@126.com

1
1 https://ror.org/03rc6as71 grid.24516.34 0000 0001 2370 4535 Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, 200124 China
2 https://ror.org/02g01ht84 grid.414902.a 0000 0004 1771 3912 The First Affiliated Hospital of Kunming Medical University, Kunming, 650032 China
14 9 2024
14 9 2024
2024
10 1 783 6 2024
6 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Cognitive impairment is a core symptom of schizophrenia (SZ), with GABAergic dysfunction in the brain potentially serving as a critical pathological mechanism underlying this condition. Intracortical inhibition (ICI), which includes short-interval intracortical inhibition (SICI) and long-interval intracortical inhibition (LICI), can be used to assess the inhibitory function of cortical GABAergic neurons. The aim of this study was to investigate the relationship between ICI and cognitive function, as well as psychopathological symptoms, in SZ patients. We recruited 130 SZ patients and 105 healthy controls (HCs). All subjects underwent paired-pulse transcranial magnetic stimulation (ppTMS) measurements, which included resting motor threshold (RMT), SICI and LICI. The cognitive function of all subjects was assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). The psychopathological symptoms of the SZ group were assessed using the Positive and Negative Syndrome Scale (PANSS). We examined group differences in MCCB scores, RMT, SICI, and LICI. Within the SZ group, we assessed the relationship between ICI and cognitive function, as well as psychopathological symptoms. Two-way ANOVA, Mann–Whitney U test, Receiver operating characteristic (ROC) curves, and partial Spearman correlation analysis were performed. The SZ group showed a worse cognitive score in all 6 cognitive dimensions of the MCCB compared to the HC group (all p < 0.05). The SZ group had lower degree of SICI and LICI compared to the HC group (both p < 0.05). ROC curves analysis showed that SICI and LICI all displayed good performance in differentiating SZ patients and HCs (both p < 0.05), and SICI exhibited a better performance, yielding an area under the curve (AUC) of 0.856 (95% CI 0.807–0.904). Furthermore, in the SZ group, SICI demonstrated a significant negative correlation with PANSS positive score, negative score, general psychopathology score, and total score (all pBonferroni < 0.05), and LICI demonstrated a significant negative correlation with PANSS positive score, general psychopathology score and total score (all pBonferroni < 0.05). Additionally, in the SZ group, SICI demonstrated a significant positive correlation with speed of processing score, working memory score, verbal learning score, visual learning score, and reasoning and problem-solving score of the MCCB (all pBonferroni < 0.05), while LICI was only weakly positive correlated with speed of processing score of the MCCB (r = 0.247, p = 0.005, pBonferroni = 0.03). Our results demonstrate that the reduction of ICI could serve as a trait-dependent in-vivo biomarker of GABAergic deficits for SZ and related cognitive impairments.

Subject terms

Schizophrenia
Biomarkers
Clinical Research Project of Shanghai Municipal Health Commission (No. 20204Y0173)Outstanding Clinical Discipline Project of Shanghai Pudong (No. PWZzk2022-19, PWYgy2021-02)https://doi.org/10.13039/501100011488 Health and Family Planning Committee of Pudong New Area (Health and Family Planning Committee of Pudong New District) Outstanding Clinical Discipline Project of Shanghai Pudong (No. PWZzk2022-19, PWYgy2021-02), Shanghai Pudong New Area Health Committee Disciplinary Leader Training Program (No. PWRd2021-06), and Science and Technology Development Fund of Shanghai Pudong New Area (No. PKJ2021-Y17).issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Schizophrenia (SZ), a chronic and debilitating disorder, affects approximately 1% of the world’s population, imposing significant burdens on patients and their families. The primary symptoms of SZ are categorized into positive symptoms, negative symptoms, and cognitive deficits1. Current research suggests that cognitive deficits may constitute the core symptom of SZ2,3, often present in the prodromal stage before the full manifestation of positive and negative symptoms4,5. Deficits in cognition exert serious adverse effects on the functional outcomes and long-term prognosis of patients with SZ6,7. However, the pathophysiological mechanisms underlying cognitive deficits in SZ remain unclear.

Emerging evidence indicates that central GABAergic inhibitory interneuron (GI) dysfunction in the brain may be a critical pathological mechanism in the onset of SZ8,9. Postmortem brain studies have demonstrated a reduction in the number and density of parvalbumin-positive (PV+) GIs in the prefrontal cortex of individuals with SZ10–12. The most consistent finding is the functional impairment of PV+ GIs in layer 3 of the prefrontal cortex. Gamma (γ) oscillations, which are ubiquitous neuroelectric activities in the brain, are closely linked to cognitive processes13–17. Studies have shown that GABAergic inhibitory function is crucial for the generation of γ oscillations, with PV+ GIs playing a prominent role18.

Intracortical inhibition (ICI) is a paired-pulse transcranial magnetic stimulation (ppTMS)-based measure that can serve as an indicator of the inhibitory function of the cerebral cortex. Research has indicated that ICI can reflect the function of GIs in the cortex19,20. By adjusting the stimulation interval to 1–4 ms or 50–200 ms, short-interval intracortical inhibition (SICI) or long-interval intracortical inhibition (LICI) can be induced, respectively. Studies have found that SICI may reflect the effects of GABAA receptors, which induce rapid inhibitory postsynaptic potentials (IPSPs)21, while LICI may reflect the effects of GABAB receptors, which induce slow IPSPs22.

Studies have indicated an association between SZ and altered ICI. However, conclusions have been varied23,24. A recent meta-analysis conducted by Lányi et al.25 has reported a robust inhibitory deficit in SICI among individuals diagnosed with SZ. However, the association between SZ and LICI, the effects of medication on ICI, and the association between ICI and cognitive function and other psychopathologies of SZ has not been thoroughly investigated. Preliminary studies have suggested that SICI may correlate with cognitive function in patients with SZ26,27. For instance, Takahashi et al.26 reported that SICI was negatively correlated with raw scores of the working memory component of the Brief Assessment of Cognition in Schizophrenia (BACS). Similarly, Mehta et al.27 found that SICI was negatively correlated with emotion processing and a global social cognition score. However, these studies involved small sample sizes and did not cover a more comprehensive range of cognitive dimensions as measured by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)28, which is a widely used cognitive assessment tool for SZ.

Based on the aforementioned research background, we hypothesize that ppTMS-based ICI may serve as a psychopathological marker of cognitive deficits in SZ. Our study has two primary aims: (1) to compare ICI and cognitive function between SZ patients and healthy controls (HCs), and (2) to explore the relationship between ICI, cognitive function, and psychopathological symptoms in SZ patients.

Materials and methods

Subjects

Patients were recruited from the Shanghai Pudong New Area Mental Health Center and the First Affiliated Hospital of Kunming Medical University. This study received approval from the Institutional Review Board of Shanghai Pudong New Area Mental Health Center (No. PDJWLL2021028), and all participants provided informed consent.

Participants met the following inclusion criteria: (1) a diagnosis of SZ according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), confirmed using the Structured Clinical Interview for DSM-IV (SCID-I/P)29; (2) aged between 18 and 60 years; (3) Han ethnicity; (4) right-handed; (5) had not taken benzodiazepines within the past 3 months; and (6) had not received transcranial magnetic stimulation (TMS) or electroconvulsive therapy within the past 3 months. The exclusion criteria included: (1) pregnancy; (2) severe physical diseases; (3) any other major Axis I disorder; and (4) substance abuse or dependence. HCs were selected based on the absence of any major Axis I disorder diagnosis and no family history of mental disorders.

We recruited 130 SZ patients (male/female: 49/81; average age: 30.92 ± 9.56 years), with 70 from the Shanghai Pudong New Area Mental Health Center and 60 from the First Affiliated Hospital of Kunming Medical University. Among the SZ patients we enrolled, 46 were first-episode drug-naïve (FEDN), 84 were receiving stable dose of antipsychotic treatment, and the antipsychotics taken by the patients were all converted to chlorpromazine equivalent doses30. Additionally, we recruited 105 sex- and age-matched HCs (male/female: 48/57; average age: 30.39 ± 12.68 years), with 49 from Shanghai and 56 from Kunming.

Clinical assessments

Demographic and clinical data were collected using a self-designed questionnaire. Psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS)31,32, while cognitive functioning was evaluated using 6 cognitive dimensions of the MCCB. These dimensions included speed of processing, working memory, verbal learning, visual learning, reasoning and problem-solving, and social cognition. Both assessors underwent thorough training on these scales, achieving an inter-rater concordance of over 0.8.

Measurement of ICI

We used the same model of TMS machine (NS5000, YIRUIDE Group, CN) and set the same parameters in both Shanghai and Kunming sites. Subjects were seated in a comfortable chair with a headrest to stabilize their head position throughout the procedure, with their arms passively supported. An electrode was placed on the right first flexor pollicis brevis muscle to record electromyograms. Single and paired-pulse stimulation was administered using a 60-mm figure-of-eight coil, with the maximum magnetic field strength at the center being 3.5T. The coil was held tangentially to the hand area of the left motor cortex, with the handle oriented backward and away from the midline at a 45° lateral angle.

Electromyography (EMG) recordings were acquired using the YIRUIDE system. The stimulation site that produced the largest Motor Evoked Potential (MEP) in the right first flexor pollicis brevis muscle was marked to ensure a consistent coil position throughout the experiment. The resting motor threshold (RMT) was defined as the lowest intensity that produced MEPs with a peak-to-peak amplitude of greater than 50 μV in at least five out of ten trials.

Measurement of target MEP: the target MEP was obtained with a stimulus intensity set to 120% of RMT, recording 5 stimulations and calculating the average value.

Measurement of SICI: a pre-stimulus (80% of RMT) was administered 2 milliseconds before the target stimulus (120% of RMT)33, recording 5 stimulations and calculating the average value as MEP1. SICI was calculated using the formula: [1 − (MEP1/target MEP)] * 100%.

Measurement of LICI: a pre-stimulus (120% of RMT) was administered 150 milliseconds before the target stimulus (120% of RMT)34, recording 5 stimulations and calculating the average value as MEP2. LICI was calculated using the formula: [1 − (MEP2/ target MEP)] * 100%.

Statistical analysis

Statistical analyses were performed using IBM SPSS, version 25.0. Continuous variables were initially assessed for normality using the Kolmogorov-Smirnov one-sample test. The normally distributed demographic data were compared using the analysis of variance (ANOVA) and described as mean ± standard deviation, whereas non-normally distributed data were compared using the Mann–Whitney U test. The categorical variables between groups were compared using the Chi-square test/Fisher exact test. Receiver operating characteristic (ROC) curves were utilized to explore the potential of using ICI factors as biomarkers to differentiate between SZ patients and HCs. Correlations between PANSS scores, MCCB scores, and ICI were evaluated using partial Spearman correlation analysis. p < 0.05 was considered statistically significant (two-tailed).

Results

Demographic, ICI, and clinical characteristics between patients and HCs

The proportion of SZ patients recruited in Shanghai is not significantly different from that of the subjects recruited in Kunming (χ2 = 1.20, p = 0.296). The demographic data of the subjects are summarized in Table 1. No significant differences in age, education, or sex distribution were observed between the SZ patient group and the healthy control group (all p > 0.05). SZ patients displayed worse cognitive scores of the MCCB compared to HCs, including lower scores in speed of processing, working memory, verbal learning, visual learning, reasoning and problem-solving, and social cognition (all p < 0.05). Additionally, SZ patients exhibited a lower degree of both SICI and LICI compared to HCs (both p < 0.05). There was no significant difference in the RMT between SZ patients and HCs (p > 0.05). Aside from significant differences in age and illness duration, no other demographic information or clinical characteristics showed statistical differences between the FEDN SZ group and the medicated SZ group.Table 1 Differences in demographic information, ICI, and clinical characteristics among HCs, FEDN SZ, and medicated SZ.

Characteristics	SZ group (N = 130)	HCs group (N = 105)	F/χ2/Z	p	
FEND SZ (N = 46)	Medicated SZ (N = 84)	
Age (years)a, mean ± SD	26.80 ± 7.43	33.20 ± 9.88###	30.39 ± 12.68	1.34	0.715	
Education (years)a, mean ± SD	12.22 ± 2.75	12.08 ± 3.05	12.63 ± 3.65	1.13	0.289	
Sex, male/female (N)b	14/32	35/49	48/57	1.54	0.232	
Illness course (years)c, median (P25–P75)	0.75 (0.275–1.00)	10.00 (3.00–17.00)###	NA	NA	NA	
Chlorpromazine equivalent dose (Mg)c, median (P25–P75)	NA	400.00 (242.50–600.00)	NA	NA	NA	
SICI (100%)c, median (P25–P75)	31.59 (23.08–41.87)	29.73 (20.48–37.38)	54.95 (41.73–68.19)	−9.37	<0.001	
LICI (100%)c, median (P25–P75)	22.94 (13.56–31.79)	25.15 (13.80–38.62)	40.00 (27.37–49.35)	−6.06	<0.001	
RMTc, median (P25–P75)	65.50 (59.50–72.50)	70.00 (60.00–76.75)	70.83 (60.00–72.00)	−0.15	0.826	
PANSS	
Positive subscorec, median (P25–P75)	13.00 (10.00–20.00)	12.00 (9.00–16.00)	NA	NA	NA	
Negative subscorec, median (P25–P75)	18.00 (12.00–26.00)	17.00 (12.25–21.75)	NA	NA	NA	
General psychopathology subscorec, median (P25–P75)	32.50 (24.00–43.25)	28.00 (23.00–40.00)	NA	NA	NA	
Total scorec, median (P25–P75)	66.00 (49.25–90.00)	57.50 (45.25–80.00)	NA	NA	NA	
MCCB	
Speed of processingc, median (P25–P75)	33.50 (26.75–40.00)	31.50 (24.25–43.75)	41.00 (36.00–49.00)	−6.42	<0.001	
Working memoryc, median (P25–P75)	39.00 (30.75–47.25)	39.50 (29.00–46.00)	42.00 (36.50–48.50)	−2.47	0.030	
Verbal learningc, median (P25–P75)	37.00 (29.75–44.25)	34.00 (27.00–42.75)	40.00 (35.00–46.50)	−3.54	<0.001	
Visual learningc, median (P25–P75)	42.00 (32.75–47.00)	40.00 (29.25–47.50)	45.00 (40.00–52.00)	−4.01	<0.001	
Reasoning and problem-solvingc, median (P25–P75)	41.00 (35.75–49.75)	37.00 (32.25–47.75)	52.00 (47.00–56.50)	−7.71	<0.001	
Social cognitionc, median (P25–P75)	29.50 (26.00–34.25)	29.00 (25.00–34.75)	36.00 (32.50–38.50)	−6.39	<0.001	
Significant differences between HCs and SZ group are highlighted in bold. Hashtag indicates significance of the comparisons between FEDN SZ and medicated SZ, ###p < 0.001.

SZ schizophrenia, FEDN first-episode drug-naïve, HCs healthy controls, SD standard deviation, NA not available, SICI short-interval intracortical inhibition, LICI long-interval intracortical inhibition, RMT resting motor threshold, PANSS Positive and Negative Syndrome Scale, MCCB MATRICS Consensus Cognitive Battery.

aComparisons between HCs and SZ patients using the analysis of variance (ANOVA).

bComparisons between HCs and SZ patients using the Chi-square test/Fisher exact test.

cComparisons between HCs and SZ patients using the Mann–Whitney U test.

SICI performs better than LICI in discriminating SZ patients from HCs as a biomarker

ROC curves were analyzed to evaluate the diagnostic value of SICI and LICI for distinguishing SZ patients from HCs. As depicted in Fig. 1, both SICI and LICI demonstrated acceptable area under the curve (AUC) for classifying SZ patients and HCs (both p < 0.05). The cutoff for SICI was 22.00 (AUC: 0.856, 95% CI: 0.807–0.904) with 68.6% sensitivity and 89.2% specificity (p < 0.001). The cutoff for LICI was 19.60 (AUC: 0.730, 95% CI: 0.665–0.795) with 68.6% sensitivity and 73.8% specificity (p < 0.001).Fig. 1 ICI in discriminating SZ patients from HCs as a biomarker.

SICI and LICI provided an acceptable AUC for discriminating patients from HCs (both p < 0.05). Among them, SICI exhibited a better performance.

Relationship between ICI and psychopathological symptoms in SZ patients

As shown in Fig. 2, controlling the age as covariate, partial Spearman correlation analysis showed that SICI was negative associated with PANSS positive score, negative score, general psychopathology score and total score in SZ patients (r = −0.226, p = 0.002, pBonferroni = 0.008; r = −0.278, p = 0.001; pBonferroni = 0.004; r = −0.311, p < 0.001, pBonferroni < 0.05; r = −0.316, p < 0.001, pBonferroni < 0.05, respectively). As shown in Fig. 3, controlling the age as covariate, partial Spearman correlation analysis showed that LICI was negative associated with PANSS positive score, general psychopathology score and total score in SZ patients (r = −0.222, p = 0.011, pBonferroni = 0.044; r = −0.289, p = 0.001, pBonferroni = 0.004; r = −0.257, p = 0.003, pBonferroni = 0.012, respectively). While, LICI was not associated with PANSS negative score in SZ patients after Bonferroni correction (r = −0.180, p = 0.041, pBonferroni = 0.164).Fig. 2 Correlation analysis between SICI and PANSS scores in SZ patients.

a There were significant negative association between SICI and PANSS positive score (r = −0.266, p = 0.002, pBonferroni = 0.008). b There were significant negative association between SICI and PANSS negative score (r = −0.278, p = 0.001, pBonferroni = 0.004). c There were significant negative association between SICI and PANSS general psychopathology score (r = −0.311, p < 0.001, pBonferroni < 0.05). d There were significant negative association between SICI and PANSS total score (r = −0.316, p < 0.001, pBonferroni < 0.05).

Fig. 3 Correlation analysis between LICI and PANSS scores in SZ patients.

a There were significant negative association between LICI and PANSS positive score (r = −0.222, p = 0.011, pBonferroni = 0.044). b There were no significant negative association between LICI and PANSS negative score (r = -0.180, p = 0.041, pBonferroni > 0.05). c There were significant negative association between LICI and PANSS general psychopathology score (r = −0.289, p = 0.001, pBonferroni = 0.004). d There were significant negative association between LICI and PANSS total score (r = −0.257, p = 0.003, pBonferroni = 0.012).

Relationship between ICI and cognitive function in SZ patients

Controlling for age as a covariate, partial Spearman correlation analysis revealed no significant relationship between SICI and MCCB social cognition score in SZ patients (r = 0.147, p = 0.095). Similarly, controlling for age as a covariate, partial Spearman correlation analysis showed no significant relationship between LICI and working memory score, verbal learning score, visual learning score, reasoning and problem-solving score, or social cognition score of the MCCB in SZ patients (all p > 0.05). As illustrated in Fig. 4, controlling for age as a covariate, partial Spearman correlation analysis indicated a positive association between SICI and speed of processing score, working memory score, verbal learning score, visual learning score, and reasoning and problem-solving score of the MCCB in SZ patients (r = 0.552, p < 0.001, pBonferroni < 0.05; r = 0.418, p < 0.001, pBonferroni < 0.05; r = 0.325, p < 0.001, pBonferroni < 0.05; r = 0.304, p < 0.001, pBonferroni < 0.05; r = 0.337, p < 0.001, pBonferroni < 0.05, respectively), while, LICI was positively associated with MCCB speed of processing score (r = 0.247, p = 0.005, pBonferroni = 0.03), only.Fig. 4 Correlation analysis between ICI and MCCB scores in SZ patients.

a There were significant positive association between SICI and MCCB speed of processing score (r = 0.552, p < 0.001, pBonferroni < 0.05). b There were significant positive association between SICI and MCCB working memory score (r = 0.418, p < 0.001, pBonferroni < 0.05). c There were significant positive association between SICI and MCCB verbal learning score (r = 0.325, p < 0.001, pBonferroni < 0.05). d There were significant positive association between SICI and MCCB visual learning score (r = 0.304, p < 0.001, pBonferroni < 0.05). e There were significant positive association between SICI and MCCB reasoning and problem-solving score (r = 0.337, p < 0.001, pBonferroni < 0.05). f There were significant positive association between LICI and MCCB speed of processing score (r = 0.247, p = 0.005, pBonferroni = 0.03).

Correlations between ICI and clinical characteristics in FEDN SZ and medicated SZ patients

Partial Spearman correlation analysis was conducted to evaluate the relationship between ICI and clinical characteristics in FEDN SZ and medicated SZ patients, controlling for age (Table 2). In both groups, no significant correlation was found between ICI and illness course or chlorpromazine equivalent dose (both p > 0.05). After Bonferroni correction, we found a significant negative correlation between SICI and the PANSS positive score in the FEDN SZ patient group (r = −0.418, p = 0.004, pBonferroni = 0.016). Additionally, in the medicated SZ patient group, significant negative correlations were found between SICI and the PANSS general psychopathology score and total score after Bonferroni correction (r = −0.289, p = 0.008, pBonferroni = 0.032; r = −0.279, p = 0.011, pBonferroni = 0.044, respectively). After Bonferroni correction, we found a significant positive correlation between SICI and speed of processing score, working memory score, verbal learning score and problem-solving score of the MCCB in the FEDN SZ patient group (r = 0.548, p < 0.001, pBonferroni < 0.01; r = 0.593, p < 0.001, pBonferroni < 0.01; r = 0.409, p = 0.005, pBonferroni = 0.030; r = 0.497, p = 0.001, pBonferroni = 0.006, respectively). In the medicated SZ patient group, significant positive correlations were found between SICI and speed of processing score and working memory score of the MCCB after Bonferroni correction (r = 0.510, p < 0.001, pBonferroni < 0.01; r = 0.321, p = 0.003, pBonferroni = 0.018, respectively).Table 2 Correlations between ICI and clinical characteristics in SZ group.

Characteristics	FEDN SZ (N = 46)	Medicated SZ (N = 84)	
SICI r	LICI r	SICI r	LICI r	
Illness course (years)	−0.121	−0.157	−0.024	−0.134	
Chlorpromazine equivalent dose (Mg)	NA	NA	−0.007	−0.162	
PANSS	
Positive subscore	−0.418#	−0.320	−0.183	−0.181	
Negative subscore	−0.334	−0.338	−0.218	−0.075	
General psychopathology subscore	−0.320	−0.330	−0.289#	−0.254	
Total score	−0.353	−0.357	−0.279#	−0.192	
MCCB	
Speed of processing	0.548##	0.328	0.510##	0.204	
Working memory	0.593##	0.146	0.321#	0.029	
Verbal learning	0.409#	0.164	0.267	0.061	
Visual learning	0.360	0.232	0.215	0.160	
Reasoning and problem-solving	0.497##	0.143	0.200	0.109	
Social cognition	0.043	0.033	0.163	0.192	
Partial Spearman correlation analysis was used to analyze correlations between characteristics. Significant correlations are highlighted in bold. The hashtag indicates a significant correlation between ICI and clinical characteristics in FEDN SZ and medicated SZ, after Bonferroni correction (#pBonferroni < 0.05; ##pBonferroni < 0.01).

FEDN first-episode drug-naïve, SZ schizophrenia, NA not available, SICI short-interval intracortical inhibition, LICI long-interval intracortical inhibition, PANSS Positive and Negative Syndrome Scale, MCCB MATRICS Consensus Cognitive Battery.

Discussion

The main findings of the present study can be summarized as follows: (1) SZ patients exhibited a lower degree of SICI and LICI compared to HCs. Furthermore, SICI demonstrated superior diagnostic value for distinguishing between SZ patients and HCs compared to LICI. (2) The degree of ICI was associated with psychopathological symptoms in SZ patients; (3) The degree of ICI was also associated with cognitive function in SZ patients; (4) Antipsychotic treatment may not impact the degree of ICI in SZ patients.

We observed a significantly reduced degree of SICI in SZ patients, and SICI exhibited better discriminatory performance for distinguishing between patients and HCs, which is consistent with findings from previous related studies26,35–37. For instance, Mehta et al. reported lower SICI in both acute episode SZ and chronic SZ patients compared to HCs, suggesting the potential utility of SICI as a biomarker for SZ27. This finding is further supported by some meta-analysis that focused on SICI in SZ patients22,25. However, some studies did not find reduced SICI in patients38,39. Fitzgerald et al.38 and Peter et al.39 reported non-significant differences in SICI among their patient cohorts, which may be attributed to confounding factors such as patient characteristics, disease heterogeneity, sample size, illness duration, and medication status. Additionally, we observed a significantly reduced degree of LICI in SZ patients, although it has a lower specificity in discriminating patients from HCs. Our findings confirmed previous meta-analysis results22,25, while providing novel evidence supporting LICI deficits in SZ patients with a larger sample size from two independent sites. Overall, our results confirmed the validity of using ICI as biomarkers for SZ.

Few studies have explored the relationships between ICI and the psychopathologies of SZ. For example, Wobrock et al.36 reported a negative correlation between cortical inhibition and total PANSS score, and Liu et al.37 found that SICI was inversely associated with positive symptoms. In our present study, we discovered that SICI was negatively correlated with PANSS positive, negative, general psychopathology, and total score in SZ patients, while LICI was negatively correlated with PANSS positive, general psychopathology, and total score in patients. This suggests that reduced cortical inhibition is inversely associated with symptom severity in SZ patients, a finding consistent with prior studies. Our results imply a stable correlation between symptom severity and deficits in both SICI and LICI. Therefore, our observation of decreased ICI in SZ patients may represent a characteristic marker of psychopathology. Future research should focus on replicating these findings and further exploring the nature of this relationship.

Our study found that the cognitive performance in 6 dimensions of the MCCB (speed of processing score, working memory score, verbal learning score, visual learning score, reasoning and problem-solving score, and social cognition score) were significantly impaired in SZ patients. SICI was positively associated with the performance in speed of processing, working memory, verbal learning, visual learning, and reasoning and problem-solving, while LICI was positively associated with speed of processing only. Our results support that abnormal ICI may be the neurophysiological mechanisms of cognitive impairment in SZ patients and may affect different cognitive dimensions through different neural or regional circuits. γ oscillation in the brain is a neurophysiological feature observed in cognitive activities40, which is closely related to cognitive processes, such as sensation and perception, information storage, retrieval, and encoding13,14. Especially, γ oscillation exhibits a prominent role in learning and memory15–17. Studies have found that GABAergic inhibitory function plays an important role in the generation of γ oscillation18, with PV+ GI playing a prominent role. Abnormal γ oscillation in the prefrontal cortex of SZ patients has been widely reported18. Animal experiments have found that activation and inhibition of PV+ GI in mice brains can selectively enhance and inhibit γ oscillation, respectively41,42. The frequency of γ oscillation is determined primarily by GABAA receptor-induced inhibitory postsynaptic currents (IPSC)43. While SICI is mainly influenced by GABAA receptors and based on the induction of IPSPs44. And this mechanism may be the reason why SICI is related to more cognitive dimensions in our study, and supporting the validity of SICI as biomarker of cognitive deficits in SZ. In contrast, LICI, which is primarily determined by GABAB receptor-induced slow IPSCs, involves slower inhibitory effects due to the metabotropic nature of G protein-coupled GABAB receptors45. A few small sample size studies have explored the LICI alterations in SZ patients and demonstrated consistent deficits in the dorsal-lateral prefrontal cortex (dlPFC) using TMS-EEG (electroencephalography) paradigms, but failed to found significant changes in the motor cortex46. With a larger sample size, we found significant decrease in LICI and correlation with some dimensions of the symptoms and cognitive deficits in SZ, even at a smaller extent than SICI. These results indicate that GABAB receptors may also be involved in the pathogenesis of SZ, possibly through a more distal pathway than GABAA receptors. Accordingly, prior studies have shown that LICI can inhibit the level of SICI through a presynaptic mechanism47, and hence may confer an indirect effect on the core pathological mechanisms of SZ.

To further explore whether ICI were trait or state dependent in SZ, and excluding the impacts of medication or illness course on ICI, we compared the ICI levels between FEDN SZ patients and medicated SZ patients. Additionally, we analyzed the correlation between ICI levels and chlorpromazine equivalent doses in medicated patients. As shown in Table 2, both medication and illness course had no significant correlation with SICI or LICI, while SICI was significantly correlated with multiple dimensions of the psychopathology and cognitive characteristics in both FEDN SZ patients and medicated SZ patients. Our result aligns with a 2024 meta-analysis25, which found no significant association between SICI and medication status or dosage. However, their conclusions were limited by differences in the characteristics of included cases and the lack of information on benzodiazepine using. Benzodiazepine treatment is known to enhance SICI23. To control for this variable, our inclusion criteria mandated that all participants should not use benzodiazepines within the three months prior to enrollment. Furthermore, the FEDN patients in our study were used to control for medication and illness course derived changes in ICI. Based on these findings, we may conclude that ICI, especially SICI, may serve as a stable trait dependent biomarker for SZ and the GABA-inhibition related cognitive deficits.

There were several limitations in this study. Firstly, the measurement of ICI was limited to the motor cortex rather than brain regions more closely related to SZ. Therefore, our findings may not fully capture the whole pathophysiological mechanisms of SZ. Additionally, even we have enrolled the largest sample size as far as we know in this research field, the limited sample size may have constraints the statistical power, especially in the stratification analyses for LICI correlations. Therefore, future research with larger longitudinal cohorts is needed to confirm and extend our findings.

Conclusions

Our results demonstrate that the reduction of ICI could serve as a trait-dependent in-vivo biomarker of GABAergic deficits for SZ and related cognitive impairments.

Abbreviations

ANOVA Analysis of variance

AUC Area under the curve

dlPFC Dorsal-lateral prefrontal cortex

EEG Electroencephalography

EMG Electromyography

FEDN First-episode drug-naïve

GI GABAergic inhibitory interneurons

HCs Healthy controls

ICI Intracortical inhibition

IPSP Inhibitory postsynaptic potentials

IPSC Inhibitory postsynaptic currents

LICI Long-interval intracortical inhibition

MATRICS Measurement and treatment research to improve cognition in schizophrenia

MCCB MATRICS consensus cognitive battery

MEP Motor evoked potential

NA Not available

PANSS Positive and Negative Syndrome Scale

ppTMS Paired-pulse transcranial magnetic stimulation

PV+ Parvalbumin-positive

RMT Resting motor threshold

ROC Receiver operating characteristic

SCID-I/ P Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition

SD Standard deviation

SICI Short-interval intracortical inhibition

SZ Schizophrenia

Acknowledgements

Thanks to all participants for assessments and interviews in our research. This work was supported by Shanghai Pudong New Area Health Committee Disciplinary Leader Training Program (No. PWRd2021-06), Science and Technology Development Fund of Shanghai Pudong New Area (No. PKJ2021-Y17), Outstanding Clinical Discipline Project of Shanghai Pudong (Nos. PWZzk2022-19, PWYgy2021-02), and the Clinical Research Project of Shanghai Municipal Health Commission (No. 20204Y0173). All funding had no role in study design, data analysis, paper submission and publication.

Author contributions

Xudong Zhao and Weiqing Liu were responsible for the study concept and design, as well as for revising and editing the manuscript. Minghuan Zhu, Yifan Xu, Qi Zhang, Xiaoyan Cheng, Lei Zhang, Fengzhi Tao, Jiali Shi, Xingjia Zhu and Zhihui Wang collected the data. Minghuan Zhu prepared the initial draft of the manuscript. All authors have contributed to and approved the final manuscript.

Data availability

The authors declare that all relevant data of this study are available within the article or from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Minghuan Zhu, Yifan Xu.
==== Refs
References

1. Zhu MH Liu ZJ Hu QY Yang JY Jin Y Zhu N Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial Mil. Med. Res. 2022 9 59 36253804
Zhu, MH., Liu, ZJ., Hu, QY., Yang, JY., Jin, Y. & Zhu, N. et al. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil. Med. Res. 9, 59 (2022).36253804
2. Geyer MA Olivier B Joels M Kahn RS From antipsychotic to anti-schizophrenia drugs: role of animal models Trends Pharmacol. Sci. 2012 33 515 521 10.1016/j.tips.2012.06.006 22810174
Geyer, M. A., Olivier, B., Joels, M. & Kahn, R. S. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends Pharmacol. Sci. 33, 515–521 (2012).22810174 10.1016/j.tips.2012.06.006
3. Young JW Geyer MA Developing treatments for cognitive deficits in schizophrenia: the challenge of translation J. Psychopharmacol. 2015 29 178 196 10.1177/0269881114555252 25516372
Young, J. W. & Geyer, M. A. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J. Psychopharmacol. 29, 178–196 (2015).25516372 10.1177/0269881114555252
4. Green MF Kern RS Braff DL Mintz J Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr. Bull. 2000 26 119 136 10.1093/oxfordjournals.schbul.a033430 10755673
Green, M. F., Kern, R. S., Braff, D. L. & Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr. Bull. 26, 119–136 (2000).10755673 10.1093/oxfordjournals.schbul.a033430
5. Furth KE Mastwal S Wang KH Buonanno A Vullhorst D Dopamine, cognitive function, and gamma oscillations: role of D4 receptors Front. Cell Neurosci. 2013 7 102 10.3389/fncel.2013.00102 23847468
Furth, K. E., Mastwal, S., Wang, K. H., Buonanno, A. & Vullhorst, D. Dopamine, cognitive function, and gamma oscillations: role of D4 receptors. Front. Cell Neurosci. 7, 102 (2013).23847468 10.3389/fncel.2013.00102
6. Xue KK Impaired large-scale cortico-hippocampal network connectivity, including the anterior temporal and posterior medial systems, and its associations with cognition in patients with first-episode schizophrenia Front. Neurosci. 2023 17 1167942 10.3389/fnins.2023.1167942 37342466
Xue, K. K. et al. Impaired large-scale cortico-hippocampal network connectivity, including the anterior temporal and posterior medial systems, and its associations with cognition in patients with first-episode schizophrenia. Front. Neurosci. 17, 1167942 (2023).37342466 10.3389/fnins.2023.1167942
7. Mihaljevic-Peles A Cognitive deficit in schizophrenia: an overview Psychiatr. Danub. 2019 31 139 142 31158113
Mihaljevic-Peles, A. et al. Cognitive deficit in schizophrenia: an overview. Psychiatr. Danub. 31, 139–142 (2019).31158113
8. Schmidt MJ Mirnics K Neurodevelopment, GABA system dysfunction, and schizophrenia Neuropsychopharmacology 2015 40 190 206 10.1038/npp.2014.95 24759129
Schmidt, M. J. & Mirnics, K. Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology 40, 190–206 (2015).24759129 10.1038/npp.2014.95
9. Cadinu D NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update Neuropharmacology 2018 142 41 62 10.1016/j.neuropharm.2017.11.045 29196183
Cadinu, D. et al. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology 142, 41–62 (2018).29196183 10.1016/j.neuropharm.2017.11.045
10. Beasley CL Reynolds GP Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics Schizophr. Res. 1997 24 349 355 10.1016/S0920-9964(96)00122-3 9134596
Beasley, C. L. & Reynolds, G. P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 24, 349–355 (1997).9134596 10.1016/S0920-9964(96)00122-3
11. Beasley CL Zhang ZJ Patten I Reynolds GP Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins Biol. Psychiatry 2002 52 708 715 10.1016/S0006-3223(02)01360-4 12372661
Beasley, C. L., Zhang, Z. J., Patten, I. & Reynolds, G. P. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol. Psychiatry 52, 708–715 (2002).12372661 10.1016/S0006-3223(02)01360-4
12. Lewis DA Hashimoto T Volk DW Cortical inhibitory neurons and schizophrenia Nat. Rev. Neurosci. 2005 6 312 324 10.1038/nrn1648 15803162
Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312–324 (2005).15803162 10.1038/nrn1648
13. Doiron B Litwin-Kumar A Rosenbaum R Ocker GK Josic K The mechanics of state-dependent neural correlations Nat. Neurosci. 2016 19 383 393 10.1038/nn.4242 26906505
Doiron, B., Litwin-Kumar, A., Rosenbaum, R., Ocker, G. K. & Josic, K. The mechanics of state-dependent neural correlations. Nat. Neurosci. 19, 383–393 (2016).26906505 10.1038/nn.4242
14. Colgin LL Rhythms of the hippocampal network Nat. Rev. Neurosci. 2016 17 239 249 10.1038/nrn.2016.21 26961163
Colgin, L. L. Rhythms of the hippocampal network. Nat. Rev. Neurosci. 17, 239–249 (2016).26961163 10.1038/nrn.2016.21
15. Csicsvari J Jamieson B Wise KD Buzsaki G Mechanisms of gamma oscillations in the hippocampus of the behaving rat Neuron 2003 37 311 322 10.1016/S0896-6273(02)01169-8 12546825
Csicsvari, J., Jamieson, B., Wise, K. D. & Buzsaki, G. Mechanisms of gamma oscillations in the hippocampus of the behaving rat. Neuron 37, 311–322 (2003).12546825 10.1016/S0896-6273(02)01169-8
16. Voytek B Oscillatory dynamics coordinating human frontal networks in support of goal maintenance Nat. Neurosci. 2015 18 1318 1324 10.1038/nn.4071 26214371
Voytek, B. et al. Oscillatory dynamics coordinating human frontal networks in support of goal maintenance. Nat. Neurosci. 18, 1318–1324 (2015).26214371 10.1038/nn.4071
17. Honkanen R Rouhinen S Wang SH Palva JM Palva S Gamma oscillations underlie the maintenance of feature-specific information and the contents of visual working memory Cereb. Cortex 2015 25 3788 3801 10.1093/cercor/bhu263 25405942
Honkanen, R., Rouhinen, S., Wang, S. H., Palva, J. M. & Palva, S. Gamma oscillations underlie the maintenance of feature-specific information and the contents of visual working memory. Cereb. Cortex 25, 3788–3801 (2015).25405942 10.1093/cercor/bhu263
18. Uhlhaas PJ Singer W Abnormal neural oscillations and synchrony in schizophrenia Nat. Rev. Neurosci. 2010 11 100 113 10.1038/nrn2774 20087360
Uhlhaas, P. J. & Singer, W. Abnormal neural oscillations and synchrony in schizophrenia. Nat. Rev. Neurosci. 11, 100–113 (2010).20087360 10.1038/nrn2774
19. Assogna M Effects of palmitoylethanolamide combined with luteoline on frontal lobe functions, high frequency oscillations, and GABAergic transmission in patients with frontotemporal dementia J. Alzheimers Dis. 2020 76 1297 1308 10.3233/JAD-200426 32623398
Assogna, M. et al. Effects of palmitoylethanolamide combined with luteoline on frontal lobe functions, high frequency oscillations, and GABAergic transmission in patients with frontotemporal dementia. J. Alzheimers Dis. 76, 1297–1308 (2020).32623398 10.3233/JAD-200426
20. McClintock SM Freitas C Oberman L Lisanby SH Pascual-Leone A Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia Biol. Psychiatry 2011 70 19 27 10.1016/j.biopsych.2011.02.031 21571254
McClintock, S. M., Freitas, C., Oberman, L., Lisanby, S. H. & Pascual-Leone, A. Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia. Biol. Psychiatry 70, 19–27 (2011).21571254 10.1016/j.biopsych.2011.02.031
21. Di Lazzaro V GABAA receptor subtype specific enhancement of inhibition in human motor cortex J. Physiol. 2006 575 721 726 10.1113/jphysiol.2006.114694 16809358
Di Lazzaro, V. et al. GABAA receptor subtype specific enhancement of inhibition in human motor cortex. J. Physiol. 575, 721–726 (2006).16809358 10.1113/jphysiol.2006.114694
22. Radhu N A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders Clin. Neurophysiol. 2013 124 1309 1320 10.1016/j.clinph.2013.01.014 23485366
Radhu, N. et al. A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders. Clin. Neurophysiol. 124, 1309–1320 (2013).23485366 10.1016/j.clinph.2013.01.014
23. di Hou M Santoro V Biondi A Shergill SS Premoli I A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia J. Psychiatry Neurosci. 2021 46 E675 E701 10.1503/jpn.210006 34933940
di Hou, M., Santoro, V., Biondi, A., Shergill, S. S. & Premoli, I. A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia. J. Psychiatry Neurosci. 46, E675–E701 (2021).34933940 10.1503/jpn.210006
24. Kaskie RE Ferrarelli F Investigating the neurobiology of schizophrenia and other major psychiatric disorders with Transcranial Magnetic Stimulation Schizophr. Res. 2018 192 30 38 10.1016/j.schres.2017.04.045 28478887
Kaskie, R. E. & Ferrarelli, F. Investigating the neurobiology of schizophrenia and other major psychiatric disorders with Transcranial Magnetic Stimulation. Schizophr. Res. 192, 30–38 (2018).28478887 10.1016/j.schres.2017.04.045
25. Lanyi O Excitation/inhibition imbalance in schizophrenia: a meta-analysis of inhibitory and excitatory TMS-EMG paradigms Schizophrenia 2024 10 56 10.1038/s41537-024-00476-y 38879590
Lanyi, O. et al. Excitation/inhibition imbalance in schizophrenia: a meta-analysis of inhibitory and excitatory TMS-EMG paradigms. Schizophrenia 10, 56 (2024).38879590 10.1038/s41537-024-00476-y
26. Takahashi S Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia Schizophr. Res. 2013 146 238 243 10.1016/j.schres.2013.02.033 23523695
Takahashi, S. et al. Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia. Schizophr. Res. 146, 238–243 (2013).23523695 10.1016/j.schres.2013.02.033
27. Mehta UM Thirthalli J Basavaraju R Gangadhar BN Association of intracortical inhibition with social cognition deficits in schizophrenia: findings from a transcranial magnetic stimulation study Schizophr. Res. 2014 158 146 150 10.1016/j.schres.2014.06.043 25048423
Mehta, U. M., Thirthalli, J., Basavaraju, R. & Gangadhar, B. N. Association of intracortical inhibition with social cognition deficits in schizophrenia: findings from a transcranial magnetic stimulation study. Schizophr. Res. 158, 146–150 (2014).25048423 10.1016/j.schres.2014.06.043
28. Nuechterlein KH The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity Am. J. Psychiatry 2008 165 203 213 10.1176/appi.ajp.2007.07010042 18172019
Nuechterlein, K. H. et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165, 203–213 (2008).18172019 10.1176/appi.ajp.2007.07010042
29. First, M., Spitzer, R., Gibbon, M. & Williams, J. Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I) (John Wiley & Sons, Inc, 2012).
30. Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics J. Clin. Psychiatry 2003 64 663 667 10.4088/JCP.v64n0607 12823080
Woods, S. W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64, 663–667 (2003).12823080 10.4088/JCP.v64n0607
31. Rodriguez-Jimenez R Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia Schizophr. Res. 2013 143 77 83 10.1016/j.schres.2012.10.020 23201306
Rodriguez-Jimenez, R. et al. Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia. Schizophr. Res. 143, 77–83 (2013).23201306 10.1016/j.schres.2012.10.020
32. Wallwork RS Fortgang R Hashimoto R Weinberger DR Dickinson D Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia Schizophr. Res. 2012 137 246 250 10.1016/j.schres.2012.01.031 22356801
Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. & Dickinson, D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 137, 246–250 (2012).22356801 10.1016/j.schres.2012.01.031
33. Kujirai T Corticocortical inhibition in human motor cortex J. Physiol. 1993 471 501 519 10.1113/jphysiol.1993.sp019912 8120818
Kujirai, T. et al. Corticocortical inhibition in human motor cortex. J. Physiol. 471, 501–519 (1993).8120818 10.1113/jphysiol.1993.sp019912
34. Valls-Sole J Pascual-Leone A Wassermann EM Hallett M Human motor evoked responses to paired transcranial magnetic stimuli Electroencephalogr. Clin. Neurophysiol. 1992 85 355 364 10.1016/0168-5597(92)90048-G 1282453
Valls-Sole, J., Pascual-Leone, A., Wassermann, E. M. & Hallett, M. Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr. Clin. Neurophysiol. 85, 355–364 (1992).1282453 10.1016/0168-5597(92)90048-G
35. Daskalakis ZJ Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation Arch. Gen. Psychiatry 2002 59 347 354 10.1001/archpsyc.59.4.347 11926935
Daskalakis, Z. J. et al. Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch. Gen. Psychiatry 59, 347–354 (2002).11926935 10.1001/archpsyc.59.4.347
36. Wobrock T Reduced cortical inhibition in first-episode schizophrenia Schizophr. Res. 2008 105 252 261 10.1016/j.schres.2008.06.001 18625547
Wobrock, T. et al. Reduced cortical inhibition in first-episode schizophrenia. Schizophr. Res. 105, 252–261 (2008).18625547 10.1016/j.schres.2008.06.001
37. Liu SK Fitzgerald PB Daigle M Chen R Daskalakis ZJ The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia Biol. Psychiatry 2009 65 503 509 10.1016/j.biopsych.2008.09.012 18950746
Liu, S. K., Fitzgerald, P. B., Daigle, M., Chen, R. & Daskalakis, Z. J. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biol. Psychiatry 65, 503–509 (2009).18950746 10.1016/j.biopsych.2008.09.012
38. Fitzgerald PB Brown TL Daskalakis ZJ Kulkarni J A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia Psychopharmacology 2002 162 74 81 10.1007/s00213-002-1068-4 12107621
Fitzgerald, P. B., Brown, T. L., Daskalakis, Z. J. & Kulkarni, J. A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology 162, 74–81 (2002).12107621 10.1007/s00213-002-1068-4
39. Eichhammer P Cortical excitability in neuroleptic-naive first-episode schizophrenic patients Schizophr. Res. 2004 67 253 259 10.1016/S0920-9964(03)00223-8 14984885
Eichhammer, P. et al. Cortical excitability in neuroleptic-naive first-episode schizophrenic patients. Schizophr. Res. 67, 253–259 (2004).14984885 10.1016/S0920-9964(03)00223-8
40. Canali P Shared reduction of oscillatory natural frequencies in bipolar disorder, major depressive disorder and schizophrenia J. Affect. Disord. 2015 184 111 115 10.1016/j.jad.2015.05.043 26074020
Canali, P. et al. Shared reduction of oscillatory natural frequencies in bipolar disorder, major depressive disorder and schizophrenia. J. Affect. Disord. 184, 111–115 (2015).26074020 10.1016/j.jad.2015.05.043
41. Cardin JA Driving fast-spiking cells induces gamma rhythm and controls sensory responses Nature 2009 459 663 667 10.1038/nature08002 19396156
Cardin, J. A. et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459, 663–667 (2009).19396156 10.1038/nature08002
42. Sohal VS Zhang F Yizhar O Deisseroth K Parvalbumin neurons and gamma rhythms enhance cortical circuit performance Nature 2009 459 698 702 10.1038/nature07991 19396159
Sohal, V. S., Zhang, F., Yizhar, O. & Deisseroth, K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698–702 (2009).19396159 10.1038/nature07991
43. Guan A The role of gamma oscillations in central nervous system diseases: mechanism and treatment Front. Cell Neurosci. 2022 16 962957 10.3389/fncel.2022.962957 35966207
Guan, A. et al. The role of gamma oscillations in central nervous system diseases: mechanism and treatment. Front. Cell Neurosci. 16, 962957 (2022).35966207 10.3389/fncel.2022.962957
44. Kuo HI Acute and chronic noradrenergic effects on cortical excitability in healthy humans Int. J. Neuropsychopharmacol. 2017 20 634 643 10.1093/ijnp/pyx026 28430976
Kuo, H. I. et al. Acute and chronic noradrenergic effects on cortical excitability in healthy humans. Int. J. Neuropsychopharmacol. 20, 634–643 (2017).28430976 10.1093/ijnp/pyx026
45. Timothy RR Kevin W Mechanisms and regulation of neuronal GABA(B) receptor-dependent signaling Curr. Top Behav. Neurosci. 2020 52 39 79 10.1007/7854_2020_129
Timothy, R. R. & Kevin, W. Mechanisms and regulation of neuronal GABA(B) receptor-dependent signaling. Curr. Top Behav. Neurosci. 52, 39–79 (2020).10.1007/7854_2020_129
46. Fatih P A systematic review of long-interval intracortical inhibition as a biomarker in neuropsychiatric disorders Front. Psychiatry 2021 12 678088 10.3389/fpsyt.2021.678088 34149483
Fatih, P. et al. A systematic review of long-interval intracortical inhibition as a biomarker in neuropsychiatric disorders. Front. Psychiatry 12, 678088 (2021).34149483 10.3389/fpsyt.2021.678088
47. Jason, C., Carolyn, G. & Robert C. Possible differences between the time courses of presynaptic and postsynaptic GABAB mediated inhibition in the human motor cortex. Exp. Brain Res. 184, 571–577 (2007).
